Cancer Family
Leukemia
CI-CAN-00000215Explore in graph →
HematologicTop-level1,769 active trials42 approved drugs708 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000215Explore in graph →
Clinical trials
8,439 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,350)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01617226 | Randomised Study of Azacitidine Versus Azacitidine With Vorinostat in Patients With AML or High Risk MDS(RAvVA) | completed | Phase 2 | 260 | University of BirminghamOTHER | 1 | May 5, 2021 | clinicaltrials |
| NCT03466320 | DEPLETHINK - LymphoDEPLEtion and THerapeutic Immunotherapy With NKR-2(DEPLETHINK) | completed | Phase 1 / Phase 2 | 21 | Celyad Oncology SAINDUSTRY | 2 | May 4, 2021 |
| clinicaltrials |
| NCT01363128 | Combination Chemotherapy and Ofatumumab in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma | completed | Phase 2 | 72 | M.D. Anderson Cancer CenterOTHER | 1 | May 3, 2021 | clinicaltrials |
| NCT01497496 | Ofatumumab/Methylprednisolone and Ofatumumab/Lenalidomide for Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) | completed | Phase 2 | 29 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Apr 27, 2021 | clinicaltrials |
| NCT03041636 | Ruxolitinib Phosphate in Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | completed | Phase 2 | 1 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 21, 2021 | clinicaltrials |
| NCT02323178 | A Study of Eltrombopag in Patients With CMML and Thrombocytopenia | completed | Phase 1 / Phase 2 | 30 | Groupe Francophone des MyelodysplasiesOTHER | 1 | Apr 20, 2021 | clinicaltrials |
| NCT02707393 | Allogeneic Stem Cell Transplantation for Children With CML | completed | Phase 2 / Phase 3 | 13 | St. Anna KinderkrebsforschungOTHER | 3 | Apr 15, 2021 | clinicaltrials |
| NCT01361334 | Pilot Clinical Trial of Pazopanib in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) or at Initial Diagnosis When no Intensive Treatment is Possible(PAZOPANIB-AML) | completed | Phase 2 | 20 | University Hospital MuensterOTHER | 1 | Apr 8, 2021 | clinicaltrials |
| NCT01441882 | Dasatinib in Treating Patients With Chronic Lymphocytic Leukemia | completed | Phase 2 | 19 | OHSU Knight Cancer InstituteOTHER | 1 | Apr 8, 2021 | clinicaltrials |
| NCT01961882 | A Phase 2 Trial to Evaluate the Efficacy and Safety of OCV-501 in Elderly Patients With Acute Myeloid Leukemia | completed | Phase 2 | 134 | Otsuka Pharmaceutical Co., Ltd.INDUSTRY | 3 | Mar 26, 2021 | clinicaltrials |
| NCT03076437 | Anti-CD19 Chimeric Antigen Receptor (CAR)-Transduced T Cell Therapy for Patients With B Cell Malignancies | completed | Phase 1 / Phase 2 | 28 | Shenzhen Institute for Innovation and Translational MedicineOTHER | 1 | Mar 19, 2021 | clinicaltrials |
| NCT01338987 | Pilot Study of Leuprolide to Improve Immune Function After Allogeneic Bone Marrow Transplantation | completed | Phase 2 | 76 | National Cancer Institute (NCI)NIH | 1 | Mar 18, 2021 | clinicaltrials |
| NCT01883362 | Standard of Care +/- Midostaurin to Prevent Relapse Post Stem Cell Transplant in Patients With FLT3-ITD Mutated AML(RADIUS) | completed | Phase 2 | 60 | Novartis PharmaceuticalsINDUSTRY | 2 | Mar 17, 2021 | clinicaltrials |
| NCT01216085 | An Exploratory Study of High-dose Glivec in Patients With CML-CP Using Molecular Endpoints(CML) | completed | Phase 2 | 10 | Novartis PharmaceuticalsINDUSTRY | 1 | Mar 10, 2021 | clinicaltrials |
| NCT00495079 | Safety and Efficacy of Marqibo in Relapsed Acute Lymphoblastic Leukemia | completed | Phase 2 | 65 | Spectrum Pharmaceuticals, IncINDUSTRY | 5 | Mar 5, 2021 | clinicaltrials |
| NCT01736943 | Bortezomib and Doxil for the Treatment of Patients With Acute Myelogenous Leukemia | completed | Phase 2 | 25 | Joseph TuscanoOTHER | 1 | Feb 24, 2021 | clinicaltrials |
| NCT01025778 | Haploidentical Stem Cell Transplantation for Children With Therapy Resistant Leukemia | completed | Phase 2 | 7 | Lund University HospitalOTHER | 1 | Feb 21, 2021 | clinicaltrials |
| NCT01502072 | Respiratory Syncytial Virus - RSV Protocol | completed | Phase 2 | 48 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 15, 2021 | clinicaltrials |
| NCT00813124 | Azacitidine After Allo Blood And Marrow Transplantation (BMT) for Chronic Myelogenous Leukemia (CML) | completed | Phase 2 | 24 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 11, 2021 | clinicaltrials |
| NCT01912274 | Safety and Efficacy Study of Pracinostat With Azacitadine in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia (AML) | completed | Phase 2 | 50 | Helsinn Healthcare SAINDUSTRY | 1 | Feb 9, 2021 | clinicaltrials |
| NCT00637052 | A Study of ARRY-520 in Patients With Advanced Myeloid Leukemia | completed | Phase 1 / Phase 2 | 36 | PfizerINDUSTRY | 1 | Feb 8, 2021 | clinicaltrials |
| NCT00489203 | Beclomethasone Dipropionate in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer | completed | Phase 2 | 140 | Fred Hutchinson Cancer CenterOTHER | 1 | Feb 3, 2021 | clinicaltrials |
| NCT03823352 | Evaluate Efficacy and Safety/Tolerability Profiles of Antroquinonol in Acute Myeloid Leukemia (AML) Adult Patients | completed | Phase 2 | 12 | Golden Biotechnology CorporationINDUSTRY | 1 | Feb 3, 2021 | clinicaltrials |
| NCT01207440 | Ponatinib for Chronic Myeloid Leukemia (CML) Evaluation and Ph+ Acute Lymphoblastic Leukemia (ALL)(PACE) | completed | Phase 2 | 449 | Ariad PharmaceuticalsINDUSTRY | 11 | Feb 2, 2021 | clinicaltrials |
| NCT01445080 | Sorafenib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia | completed | Phase 1 / Phase 2 | 70 | National Cancer Institute (NCI)NIH | 2 | Feb 2, 2021 | clinicaltrials |
| NCT03755947 | Ibrutinib, Obinutuzumab and Venetoclax for Patients With Chronic Lymphocytic Leukemia | completed | Phase 2 | 3 | Grupo Cooperativo de Hemopatías MalignasOTHER | 1 | Feb 2, 2021 | clinicaltrials |
| NCT03289455 | CD19 /22 CAR T Cells (AUTO3) for the Treatment of B Cell Acute Lymphoblastic Leukemia (ALL)(AMELIA) | completed | Phase 1 / Phase 2 | 23 | Autolus LimitedINDUSTRY | 1 | Feb 1, 2021 | clinicaltrials |
| NCT00469014 | Busulfan, Fludarabine, Clofarabine With Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia | completed | Phase 2 | 72 | M.D. Anderson Cancer CenterOTHER | 1 | Jan 26, 2021 | clinicaltrials |
| NCT01856283 | Nilotinib 300 mg BID in Newly Diagnosed CP-CML Patients to Verify Disappearance of CD34+/Lin-Ph+ Cells | completed | Phase 2 | 87 | Niguarda HospitalOTHER | 1 | Jan 13, 2021 | clinicaltrials |
| NCT00621244 | A Study of Oral LBH589 in Adult Patients With Advanced Hematological Malignancies | completed | Phase 1 / Phase 2 | 175 | Novartis PharmaceuticalsINDUSTRY | 3 | Jan 5, 2021 | clinicaltrials |
| NCT01930162 | Safety and Tolerability of HSC835 in Patients With Hematological Malignancies Undergoing Single Umbilical Cord Blood Transplant(UCBT) | completed | Phase 2 | 9 | Novartis PharmaceuticalsINDUSTRY | 1 | Jan 5, 2021 | clinicaltrials |
| NCT01180322 | Trial Evaluating Induction Therapy With Idarubicin and Etoposide Plus Sequential or Concurrent Azacitidine and Maintenance Therapy With Azacitidine(azacitidine) | completed | Phase 2 | 277 | University of UlmOTHER | 2 | Dec 31, 2020 | clinicaltrials |
| NCT01474681 | Safety and Tolerability of HSC835 in Patients With Hematological Malignancies | completed | Phase 1 / Phase 2 | 27 | Novartis PharmaceuticalsINDUSTRY | 1 | Dec 30, 2020 | clinicaltrials |
| NCT01720225 | Decitabine Versus Azacitidine in Myelodysplastic Syndrome Patients With Low and Intermediate-1 Risk | completed | Phase 2 | 113 | M.D. Anderson Cancer CenterOTHER | 1 | Dec 24, 2020 | clinicaltrials |
| NCT00831766 | Idarubicin + Cytarabine and Lenalidomide in Patients With Myelodysplastic Syndrome (MDS), Acute Myeloid Leukemia (AML) | completed | Phase 1 / Phase 2 | 51 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Dec 22, 2020 | clinicaltrials |
| NCT00005797 | Bone Marrow Transplant in Treating Patients With Hematologic Cancers | completed | Phase 2 | 125 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Dec 10, 2020 | clinicaltrials |
| NCT00612716 | Donor Stem Cell Transplant in Treating Patients With Previously Treated Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia | completed | Phase 2 | 6 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Dec 9, 2020 | clinicaltrials |
| NCT00067028 | Clofarabine Combinations in Relapsed/Refractory Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS) and Myeloid Blast Phase Chronic Myeloid Leukemia (CML) | completed | Phase 2 | 116 | M.D. Anderson Cancer CenterOTHER | 1 | Dec 8, 2020 | clinicaltrials |
| NCT00384228 | A Phase l/ll Study of AMN107 in Adult Patients With Glivec-intolerant CML or Relapsed-refractory Ph+ALL | completed | Phase 1 / Phase 2 | 42 | Novartis PharmaceuticalsINDUSTRY | 1 | Dec 8, 2020 | clinicaltrials |
| NCT01249820 | Pharmacokinetics of Anidulafungin (Ecalta ®) Intravenous Given to Patients at High Risk for Developing Invasive Fungal Disease(ANIDULAPK) | completed | Phase 2 | 26 | Radboud University Medical CenterOTHER | 1 | Dec 8, 2020 | clinicaltrials |
| NCT01279473 | Study to Evaluate Nilotinib in Adult Patients With Imatinib-resistant or Imatinib-intolerant Chronic Myelogenous Leukemia (CML), or Relapse/Refractory Ph+ Acute Lymphoblastic Leukemia (ALL) (Extension Study) | completed | Phase 1 / Phase 2 | 42 | Novartis PharmaceuticalsINDUSTRY | 1 | Dec 8, 2020 | clinicaltrials |
| NCT00671658 | Modified Hyper-CVAD (Cyclophosphamide, Vincristine, Adriamycin, and Dexamethasone) Program for Acute Lymphoblastic Leukemia | completed | Phase 2 | 220 | M.D. Anderson Cancer CenterOTHER | 1 | Dec 3, 2020 | clinicaltrials |
| NCT02046122 | Adoptive Transfer of Haplo-identical DLI for AML and MDS | completed | Phase 1 / Phase 2 | 19 | Duke UniversityOTHER | 1 | Dec 3, 2020 | clinicaltrials |
| NCT02228096 | Study of Efficacy and Safety of CTL019 in Pediatric ALL Patients(ENSIGN) | completed | Phase 2 | 75 | Novartis PharmaceuticalsINDUSTRY | 1 | Nov 23, 2020 | clinicaltrials |
| NCT02799147 | GVHD Prophylaxis With Post-transplantation Bendamustine in Refractory Leukemia | completed | Phase 1 / Phase 2 | 27 | St. Petersburg State Pavlov Medical UniversityOTHER | 1 | Nov 23, 2020 | clinicaltrials |
| NCT00305682 | Non-Myeloablative Conditioning for Unrelated Donor Umbilical Cord Blood Transplant | completed | Phase 2 | 295 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Nov 19, 2020 | clinicaltrials |
| NCT02092324 | Ruxolitinib Phosphate in Treating Patients With Chronic Neutrophilic Leukemia or Atypical Chronic Myeloid Leukemia | completed | Phase 2 | 51 | OHSU Knight Cancer InstituteOTHER | 1 | Nov 16, 2020 | clinicaltrials |
| NCT00858117 | A Phase II Trial of Alemtuzumab and Rituximab in Patients With Previously Untreated CLL | completed | Phase 2 | 30 | Northwestern UniversityOTHER | 1 | Nov 6, 2020 | clinicaltrials |
| NCT02638467 | Allogeneic Stem Cell Transplantation in Chronic Myeloid Leukemia Failing TKIs Therapy | completed | Phase 2 | 2 | University of Milano BicoccaOTHER | 1 | Nov 5, 2020 | clinicaltrials |
Data updated 23 days agoSource updated May 5, 2021source: clinicaltrials